About Daiichi Sankyo
Daiichi Sankyo is a global pharmaceutical company with origins in Japan. We draw upon a rich legacy of more than 120 years of innovation and a robust pipeline of promising new medicines to help patients across multiple therapeutic areas including cancer, cardiovascular disease, infectious disease, and autoimmune conditions. We currently operate in 29 countries with over 17,000 employees committed to our purpose of enriching people’s quality of life.
Our cancer therapies
Today, we are poised to redefine the treatment of cancer with our proprietary DXd antibody drug conjugate (ADC) technology. We are currently evaluating six ADCs in our portfolio for more than 40 different indications for cancers with unmet needs in clinical trials worldwide.
We are committed to bringing this versatile technology to the people who need it, as quickly as possible. We have an important partnership with AstraZeneca on our most advanced ADC directed for HER2-expressing cancers, Enhertu®, as well as another ADC directed at TROP2-expressing cancers. In addition, we have a further four ADCs in earlier phase clinical trials.
Our commitment to the future of Australian cancer care
We believe now is the right time for us to make a difference to the lives of Australians impacted by cancer.
“We are poised to redefine the treatment of cancer with our proprietary DXd antibody drug conjugate (ADC) technology.”
Australia is home to some of the world's best cancer researchers and already has the research infrastructure and regulatory frameworks for rapid approval and commencement of clinical trials. We are looking to foster strong collaboration with Australian experts, including those impacted by cancer, to identify the next generation of breakthroughs in cancer treatment as we continue to progress our pipeline. We have worked with over 40 Australian sites in over 10 clinical trials evaluating our DXd ADCs, with additional studies planned.
We will strive to enhance the future of Australian cancer care together with the community. We are growing our Australian team of people with a passion for innovation and compassion for patients and bring our technology which is poised to change outcomes across multiple tumour types.
To transform the future of Australian cancer care and enrich the quality of life of people impacted by cancer, our commitment is to develop new ideas and innovations in partnership with local researchers, clinicians, patients, patient advocates and government.
For more information, please visit www.daiichisankyo.com
Address: Suite 3.03, Building A, Foundation Park, 11 Talavera Rd, Macquarie Park, NSW 2113, Australia
Phone: +61 2 8527 9909